MedTrace Logo

Single and Multiple Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of AG10

NCT03294707 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2024-09-19

No results posted yet for this study

Summary

This is a single center, prospective, randomized, placebo-controlled study of AG10 in healthy adult subjects

Conditions

  • Amyloid Cardiomyopathy, Transthyretin-Related

Interventions

DRUG

AG10 oral tablet

Active single ascending dose

DRUG

Placebo Oral Tablet

Placebo single dose

Sponsors & Collaborators

  • Celerion

    collaborator INDUSTRY

  • Eidos Therapeutics, a BridgeBio company

    lead INDUSTRY

Principal Investigators

  • Terry O'Reilly, M.D. · Celerion

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-09-11
Primary Completion
2018-02-05
Completion
2018-05-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03294707 on ClinicalTrials.gov